1-10 of 10
Charles Dumontet
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction

Available to Purchase
Ivana Spasevska, Eva Laure Matera, Kamel Chettab, Jade Ville, Marie Potier-Cartereau, Lars Petter Jordheim, Catherine Thieblemont, Denis Sahin, Christian Klein, Charles Dumontet
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (11): 2371–2381.
https://doi.org/10.1158/1535-7163.MCT-19-0839
Published: 03 November 2020
View articletitled, Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction
Open the PDF for Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction in another window
Includes: Supplementary data
Journal Articles

A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells

Free
Matthieu Broussas, Nicolas Boute, Barbara Akla, Sven Berger, Charlotte Beau-Larvor, Thierry Champion, Alain Robert, Alain Beck, Jean-François Haeuw, Liliane Goetsch, Christian Bailly, Charles Dumontet, Thomas Matthes, Nathalie Corvaia, Christine Klinguer-Hamour
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (8): 1890–1899.
https://doi.org/10.1158/1535-7163.MCT-16-0041
Published: 03 August 2016
View articletitled, A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells
Open the PDF for A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells in another window
Journal Articles

Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies

Free
Sébastien Cornet, Doriane Mathé, Kamel Chettab, Anne Evesque, Eva-Laure Matera, Olivier Trédan, Charles Dumontet
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (6): 1238–1247.
https://doi.org/10.1158/1535-7163.MCT-15-0759
Published: 02 June 2016
View articletitled, Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies
Open the PDF for Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies in another window
Includes: Supplementary data
Journal Articles

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Free
Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Tanja Fauti, Gunter Muth, Doris Ziegler-Landesberger, Erwin Van Puijenbroek, Sabine Lang, Minh Ngoc Duong, Lina Reslan, Christian A. Gerdes, Thomas Friess, Ute Baer, Helmut Burtscher, Michael Weidner, Charles Dumontet, Pablo Umana, Gerhard Niederfellner, Marina Bacac, Christian Klein
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2013) 12 (10): 2031–2042.
https://doi.org/10.1158/1535-7163.MCT-12-1182
Published: 07 October 2013
View articletitled, Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Open the PDF for Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models in another window
Includes: Multimedia, Supplementary data
Journal Articles

Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells

Free
Rouba Hage-Sleiman, Stéphanie Herveau, Eva-Laure Matera, Jean-Fabien Laurier, Charles Dumontet
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (2): 303–312.
https://doi.org/10.1158/1535-7163.MCT-10-0568
Published: 08 February 2011
View articletitled, Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells
Open the PDF for Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

Free
Stephane Dalle, Lina Reslan, Timothee Besseyre de Horts, Stephanie Herveau, Frank Herting, Adriana Plesa, Thomas Friess, Pablo Umana, Christian Klein, Charles Dumontet
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (1): 178–185.
https://doi.org/10.1158/1535-7163.MCT-10-0385
Published: 10 January 2011
View articletitled, Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
Open the PDF for Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101 in another window
Includes: Supplementary data
Journal Articles

Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription leading predominantly to down-regulation of short-lived mRNA

Free
Stéphane Vispé, Luc DeVries, Laurent Créancier, Jérome Besse, Sophie Bréand, David J. Hobson, Jesper Q. Svejstrup, Jean-Philippe Annereau, Didier Cussac, Charles Dumontet, Nicolas Guilbaud, Jean-Marc Barret, Christian Bailly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (10): 2780–2790.
https://doi.org/10.1158/1535-7163.MCT-09-0549
Published: 12 October 2009
View articletitled, Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription leading predominantly to down-regulation of short-lived mRNA
Open the PDF for Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription leading predominantly to down-regulation of short-lived mRNA in another window
Includes: Supplementary data
Journal Articles

Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies

Free
Charles Dumontet, Mary Ann Jordan, Francis F.Y. Lee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (1): 17–25.
https://doi.org/10.1158/1535-7163.MCT-08-0986
Published: 12 January 2009
View articletitled, Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies
Open the PDF for Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies in another window
Journal Articles

Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel

Free
Pascal Sève, John Mackey, Sylvie Isaac, Olivier Trédan, Pierre-Jean Souquet, Maurice Pérol, Raymond Lai, Alain Voloch, Charles Dumontet
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (12): 2001–2007.
https://doi.org/10.1158/1535-7163.MCT-05-0244
Published: 22 December 2005
View articletitled, Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel
Open the PDF for Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel in another window
Journal Articles

Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells

Free
Lars Petter Jordheim, Olivier Guittet, Michel Lepoivre, Carlos M. Galmarini, Charles Dumontet
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (8): 1268–1276.
https://doi.org/10.1158/1535-7163.MCT-05-0121
Published: 10 August 2005
View articletitled, Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells
Open the PDF for Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells in another window